MiNK Therapeutics director awarded RSU shares

Corvese Brian reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Corvese Brian reported acquisition or exercise transactions in this Form 4 filing.

MiNK Therapeutics director Brian Corvese received stock-based board compensation rather than cash. He was granted 1,444 restricted stock units (RSUs) at $12.38 and 1,640 RSUs at $10.90 as compensation for board and committee retainers. The RSUs vest one month from each grant, and his direct common stock holdings total 53,137 shares after these awards. RSUs for Q1 2026 board and committee compensation were reported late due to an administrative error.

Insider Trade Summary

Grant/Award: 3,084 shares

Grant/Award 2 txns

Insider Corvese Brian

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	1,444	$12.38	$18K
Grant/Award	Common Stock	1,640	$10.90	$18K

Holdings After Transaction: Common Stock — 53,137 shares (Direct)

Footnotes (2)

1. F1. The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.
2. F2. Due to an administrative error, the RSUs for Q1 2026 Board and committee compensation were not filed timely.

Key Figures

RSU grant 1: 1,444 shares at $12.38 RSU grant 2: 1,640 shares at $10.90 Total shares held: 53,137 shares +1 more

4 metrics

RSU grant 1 1,444 shares at $12.38 Common Stock RSUs granted on 2026-06-01

RSU grant 2 1,640 shares at $10.90 Common Stock RSUs granted on 2026-03-02

Total shares held 53,137 shares Direct common stock ownership after transactions

RSU grants count 2 awards Grant, award, or other acquisition transactions

Key Terms

restricted stock units ("RSUs"), contingent right, vest, in lieu of cash retainers, +1 more

5 terms

restricted stock units ("RSUs") financial

"The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

contingent right financial

"RSUs, which represent a contingent right to receive one share of Common Stock for each RSU"

vest financial

"The RSUs will vest one month from the grant date"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

in lieu of cash retainers financial

"The RSUs were received in lieu of cash retainers for board and committee compensation"

administrative error other

"Due to an administrative error, the RSUs for Q1 2026 Board and committee compensation were not filed timely"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did MiNK Therapeutics (INKT) report for Brian Corvese?

MiNK Therapeutics reported that director Brian Corvese received two stock-based awards. He was granted 1,444 restricted stock units and 1,640 restricted stock units as board and committee compensation, both settled in common stock rather than cash retainers.

How many MiNK Therapeutics (INKT) shares does Brian Corvese hold after these grants?

After these grants, Brian Corvese directly holds 53,137 shares of MiNK Therapeutics common stock. This total reflects his position following the two restricted stock unit awards disclosed in the Form 4 insider transaction report.

At what prices were Brian Corvese’s MiNK Therapeutics RSUs valued?

The RSU awards to Brian Corvese were valued using per-share prices. One grant for 1,444 restricted stock units used a $12.38 share price, while the second grant for 1,640 restricted stock units used a $10.90 share price for reporting purposes.

Why did MiNK Therapeutics grant RSUs to Brian Corvese instead of cash?

The RSUs were granted to Brian Corvese in lieu of cash retainers for board and committee compensation. Each restricted stock unit represents a contingent right to receive one share of common stock, aligning part of his compensation with MiNK Therapeutics equity.

When do Brian Corvese’s MiNK Therapeutics RSUs vest?

The restricted stock units granted to Brian Corvese will vest one month from the respective grant date. Upon vesting, each RSU entitles him to receive one share of MiNK Therapeutics common stock, as described in the Form 4 footnotes.

Was any MiNK Therapeutics (INKT) board compensation reported late in this filing?

Yes. The filing states that RSUs for Q1 2026 board and committee compensation were not filed timely due to an administrative error. This note clarifies that the delay related to reporting, not to the grant itself or its terms.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/02/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Corvese Brian

(Last) (First) (Middle)

149 FIFTH AVENUE, SUITE 500

(Street)

NEW YORK NEW YORK 10010

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MiNK Therapeutics, Inc. [ INKT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		A		1,640	A	$10.9(2)	51,693	D
Common Stock	06/01/2026		A		1,444	A	$12.38(1)	53,137	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.

2. Due to an administrative error, the RSUs for Q1 2026 Board and committee compensation were not filed timely.

	By: /s/ Melissa Orilall, Attorney-in-Fact	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)